Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Previous studies suggested IV immunoglobulin (IVIG) may reduce relapses in relapsing-remitting multiple sclerosis (RRMS).
• However, these studies were often small and used varying treatment protocols.
• A new formulation, IGIV-C 10%, was investigated for its efficacy and safety in RRMS.

Purpose of the Study:

• To evaluate the efficacy of two doses of IGIV-C 10% in suppressing clinical and MRI disease activity in RRMS patients.
• To assess the safety profile of IGIV-C 10% in this patient population.

Main Methods:

• A multicenter, randomized, double-blind, placebo-controlled trial involving 127 RRMS patients.
• Patients received 0.2 g/kg or 0.4 g/kg of IGIV-C 10%, or placebo (0.1% albumin) every 4 weeks for 48 weeks.
• Primary endpoint: proportion of relapse-free patients; Secondary endpoint: lesion activity on MRI.

Main Results:

• No statistically significant difference in the proportion of relapse-free patients between IVIG and placebo groups after 1 year.
• No significant difference in cumulative new active MRI lesions between treatment groups.
• Adverse event rates were similar across all groups, indicating good tolerability.

Conclusions:

• IV immunoglobulin (IVIG) treatment at doses of 0.2 to 0.4 g/kg did not demonstrate a beneficial effect in RRMS patients.
• The findings question the clinical utility of IVIG for managing relapsing-remitting multiple sclerosis.
• IVIG was well-tolerated, but efficacy was not substantiated in this trial.